A Phase 1 Study of Enzalutamide Implants in Prostate Cancer

Study Description

Evaluating the Safety and Localized Delivery of Enzalutamide Implants in Prostate Cancer Patients Before Surgery

Study Details

Registry ID:

NCT06257693

Conditions:

Prostate Adenocarcinoma

Phase:

Phase 1

Target Enrollment:

45 participants

Start Date:

June 21, 2024

Age Range:

21–999 years

Gender:

Male

Healthy Volunteers:

No

Study Locations (10 sites)

• Atlantic Urology Specialists
  Myrtle Beach, South CarolinaUnited States, United States
• Virginia Commonwealth University
  Richmond, VirginiaUnited States, United States
• Johns Hopkins University School of Medicine
  Baltimore, MarylandUnited States, United States
• National Institutes of Health Clinical Center
  Bethesda, MarylandUnited States, United States
• Mary Bird Cancer Center
  Metairie, LouisianaUnited States, United States
• Northwestern University
  Chicago, IllinoisUnited States, United States
• Aurora Urology
  Milwaukee, WisconsinUnited States, United States
• Urology Associates of Central California
  Fresno, CaliforniaUnited States, United States
• University of California San Francisco Helen Diller Family Comprehensive Cancer Center
  San Francisco, CaliforniaUnited States, United States
• VA Portland Health Care System
  Portland, OregonUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →